{"id":137854,"date":"2026-07-22T00:54:29","date_gmt":"2026-07-22T00:54:29","guid":{"rendered":"https:\/\/thelatinpostny.com\/?p=137854"},"modified":"2026-07-22T00:54:29","modified_gmt":"2026-07-22T00:54:29","slug":"novo-nordisk-acusa-a-eli-lilly-de-publicidad-enganosa-sobre-medicamentos-contra-obesidad","status":"publish","type":"post","link":"https:\/\/thelatinpostny.com\/?p=137854","title":{"rendered":"Novo Nordisk acusa a Eli Lilly de publicidad enga\u00f1osa sobre medicamentos contra obesidad"},"content":{"rendered":"<p>El gigante farmac\u00e9utico dan\u00e9s\u00a0<strong>Novo Nordisk<\/strong>, fabricante de los tratamientos contra la obesidad y la diabetes\u00a0<strong>Wegovy<\/strong>\u00a0y\u00a0<strong>Ozempic<\/strong>, anunci\u00f3 el martes una\u00a0<strong>demanda<\/strong>\u00a0en Estados Unidos contra su principal competidor, el laboratorio estadounidense\u00a0<strong>Eli Lilly<\/strong>, por \u00ab<strong>publicidad enga\u00f1osa<\/strong>\u00ab.<\/p>\n<p>La compa\u00f1\u00eda danesa denuncia \u00abuna\u00a0<strong>campa\u00f1a publicitaria nacional<\/strong>\u00a0enga\u00f1osa que genera confusi\u00f3n entre los consumidores al utilizar\u00a0<strong>estudios obsoletos<\/strong>\u00a0para comparar las\u00a0<strong>dosis inyectables<\/strong>\u00a0m\u00e1s altas de los medicamentos de Lilly con dosis m\u00e1s bajas de los f\u00e1rmacos inyectables de\u00a0<strong>Novo Nordisk<\/strong>\u00a0destinados al tratamiento de la obesidad y la\u00a0<strong>diabetes de tipo 2<\/strong>\u00ab, se\u00f1ala en su comunicado.<\/p>\n<h2><strong>Comparaciones tratamientos<\/strong><\/h2>\n<p><strong>Novo Nordisk<\/strong>\u00a0critica las comparaciones de sus tratamientos con los medicamentos estrella de su competidor estadounidense,\u00a0<strong>Mounjaro<\/strong>\u00a0y\u00a0<strong>Zepbound<\/strong>.<\/p>\n<ul class=\"list-text\">\n<li><strong>Novo Nordisk<\/strong>\u00a0ha desarrollado una mol\u00e9cula, el\u00a0<strong>semaglutida<\/strong>, mientras que el laboratorio estadounidense\u00a0<strong>Eli Lilly<\/strong>\u00a0ha creado la mol\u00e9cula\u00a0<strong>tirzepatida<\/strong>.<\/li>\n<\/ul>\n<p>El grupo dan\u00e9s cita en particular una\u00a0<strong>campa\u00f1a publicitaria<\/strong>\u00a0basada en una comparaci\u00f3n, seg\u00fan \u00e9l \u00abobsoleta\u00bb, entre\u00a0<strong>Zepbound<\/strong>\u00a0y\u00a0<strong>Wegovy<\/strong>, al no mencionar la dosis m\u00e1s alta de\u00a0<strong>Wegovy<\/strong>.<\/p>\n<p>Los tratamientos contra la obesidad imitan una\u00a0<strong>hormona<\/strong>\u00a0secretada por los intestinos, el\u00a0<strong>GLP-1<\/strong>. Pueden utilizarse para perder peso o para tratar la\u00a0<strong>diabetes de tipo 2<\/strong>, la m\u00e1s extendida.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El gigante farmac\u00e9utico dan\u00e9s\u00a0Novo Nordisk, fabricante de los tratamientos contra la obesidad y la diabetes\u00a0Wegovy\u00a0y\u00a0Ozempic, anunci\u00f3 el martes una\u00a0demanda\u00a0en Estados Unidos contra su principal competidor, el laboratorio estadounidense\u00a0Eli Lilly, por \u00abpublicidad enga\u00f1osa\u00ab. La compa\u00f1\u00eda danesa denuncia \u00abuna\u00a0campa\u00f1a publicitaria nacional\u00a0enga\u00f1osa que genera confusi\u00f3n entre los consumidores al utilizar\u00a0estudios obsoletos\u00a0para comparar las\u00a0dosis inyectables\u00a0m\u00e1s altas de los medicamentos [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":137856,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-137854","post","type-post","status-publish","format-standard","has-post-thumbnail","category-salud"],"_links":{"self":[{"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=\/wp\/v2\/posts\/137854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=137854"}],"version-history":[{"count":1,"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=\/wp\/v2\/posts\/137854\/revisions"}],"predecessor-version":[{"id":137857,"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=\/wp\/v2\/posts\/137854\/revisions\/137857"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=\/wp\/v2\/media\/137856"}],"wp:attachment":[{"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=137854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=137854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thelatinpostny.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=137854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}